Biomarkers and methods of use for radiation-induced lung injury
View Patent ↗The present disclosure is directed to methods (e.g., in vitro methods) for use of nicotinamide phosphoribosyltransferase (NAMPT) as a biomarker in radiation-induced lung injury (RILI). Provided herein is an in vitro method for the diagnosis, prognosis, and/or monitoring of RILI in a human subject by providing a tissue or plasma sample from the subject and detecting the level of NAMPT therein, wherein a higher level of NAMPT in the tissue or plasma sample from the subject compared to a healthy control or a reference value is indicative for the presence of RILI in the subject. Further provided herein is a method of detecting NAMPT in a human subject by obtaining a biological sample from the subject, detecting the presence of NAMPT in the sample by contacting the sample with a capture agent that specifically binds NAMPT, and detecting binding between NAMPT and the capture agent.
1. A method of reducing inflammation in a human subject to address radiation-induced lung injury (RILI), said method comprising:
(a) detecting a level of nicotinamide phosphoribosyltransferase (NAMPT) in a biological sample obtained from the human subject by contacting the biological sample with a capture agent that specifically binds NAMPT;
(b) comparing the level of NAMPT to a healthy control or a reference value, wherein a higher level of NAMPT in the biological sample compared to the healthy control or the reference value is indicative of the presence of RILI in the human subject; and
(c) administering to the subject a NAMPT inhibitor, the level of NAMPT in the biological sample being higher than the healthy control or reference value.
2. The method of claim 1 , wherein the capture agent detects binds NAMPT protein and binding between the NAMPT protein and the capture agent is detected by autoradiography, western blot analysis, immunohistochemistry (IHC), or ELISA.
3. The method of claim 2 , wherein the capture agent is an anti-NAMPT antibody.
4. The method of claim 3 , wherein the anti-NAMPT antibody is radiolabeled.
5. The method of claim 1 , wherein the capture agent detects NAMPT mRNA and binding between NAMPT and the capture agent is detected by RT-PCR.
6. The method of claim 5 , wherein the capture agent is a primer pair complimentary to all or a portion of the nucleic acid sequence of SEQ ID NO: 1.
7. The method of claim 1 , wherein the human subject shows symptoms of RILI.
8. The method of claim 1 , wherein the human subject is at a risk of developing RILI.
9. The method of claim 8 , wherein the human subject is a cancer patient undergoing radiotherapy.
10. The method of claim 8 , wherein the human subject is exposed to ionizing radiation (IR).
11. The method of claim 9 , wherein the human subject is a cancer patient undergoing thoracic radiotherapy.
12. The method of claim 1 , wherein the healthy control or the reference value is a level of NAMPT expression in a control subject.
13. The method of claim 12 , wherein the control subject is a subject without RILI.
14. The method of claim 13 , wherein the control subject is a subject without any lung disease.
15. The method of claim 1 , wherein the biological sample is a tissue sample or a plasma sample.
16. The method of claim 15 , wherein the sample is a tissue sample and the tissue is lung tissue, thoracic tissue, or tonsillar tissue.
17. The method of claim 1 , wherein the NAMPT inhibitor is a polypeptide inhibitor.
18. The method of claim 17 , wherein the NAMPT inhibitor is an anti-NAMPT antibody.
19. The method of claim 1 , wherein the NAMPT inhibitor is a nucleic acid inhibitor.
20. A method of reducing inflammation in a human subject exposed to ionizing radiation, the method comprising:
(a) detecting a level of nicotinamide phosphoribosyltransferase (NAMPT) in a biological sample obtained from the human subject by contacting the biological sample with a capture agent that specifically binds NAMPT;
(b) comparing the level of NAMPT to a healthy control or a reference value, wherein a higher level of NAMPT in the biological sample compared to the healthy control or the reference value is indicative of presence of radiation-induced lung injury in the human subject; and
(c) administering to the subject an anti-NAMPT antibody, the level of NAMPT in the biological sample being higher than the healthy control or reference value.